Sponsor’s Guide to IRB Approval (Part III): Building an IRB-Ready Informed Consent
For sponsors, informed consent is one of the most visible signals of study quality during IRB review. It’s also a frequent source of avoidable delays. Consent forms that are overly technical, inconsistent with the protocol, vague about risk, or unclear about payment and participant responsibilities often trigger stipulations that slow the IRB approval process and create preventable revision cycles.
A strong informed consent form does more than satisfy a regulatory requirement. As the FDA states in its March 2024 draft guidance, informed consent should begin with key information and be presented in a way that facilitates understanding of why someone might or might not want to participate. It helps potential participants understand what the study involves, what the risks and uncertainties are, what choices they have, and what will happen if they decide to move forward.
When sponsors approach informed consent as both a document and a consent process, they become better positioned to present key information clearly, communicate risks and uncertainties transparently, include required disclosures in a usable format, and keep the consent form aligned with the protocol to support a more efficient path to IRB approval.
Designing an informed consent process that supports IRB approval
A participant-centered informed consent document should explain the study in clear, concise language written at an appropriate reading level.
That sounds straightforward, but in practice, many consent forms still rely too heavily on technical protocol language. Scientific precision matters, but participants shouldn’t have to decode technical terms, dense medical phrasing, or operational detail that obscures the core information they need to make a decision.
That approach is consistent with the FDA’s draft guidance, which recommends presenting key information first and tailoring it to what prospective participants would likely consider most important.
Just as important, sponsors should reinforce that informed consent is an ongoing communication process rather than a one-time signature event. The form itself should outline:
- How communication will continue throughout the study.
- How participants’ questions will be handled.
- How updates will be communicated.
- Whether re-consenting may be required if the protocol changes or new risk information emerges.
Clear risk disclosure and communication of uncertainty
Risk disclosure is one of the most heavily scrutinized parts of any informed consent document, and for good reason: Participants need a balanced and understandable description of what may happen if they join the study. IRBs look closely at whether the consent form accurately reflects the risks described in the protocol and whether the language is clear enough for a non-clinical audience.
Sponsors should transparently describe foreseeable risks, discomforts, and unknowns, without minimizing language. As referenced in the FDA’s draft guidance, the most important reasonably foreseeable risks should be surfaced early in the consent materials so participants can quickly understand the factors that will likely shape their decision.
In practice, that means:
- Avoiding phrasing that downplays severity or implies certainty that doesn’t exist.
- Giving participants a realistic understanding of what is known, what may occur, and what remains uncertain.
It’s also important to distinguish among different categories of risk. For example:
- Known risks should be described clearly and consistently with the protocol and supporting study materials.
- Potential risks should be identified as risks that may occur based on available information.
- Unforeseeable risks should be acknowledged when appropriate, especially in studies involving investigational products or limited safety experience.
The FDA’s draft guidance supports this, indicating that risks, benefits, study duration, and major procedures are the kinds of topics that should be surfaced clearly in the key up-front information, rather than later in the document when readers may have to work harder to piece those details together.
For example, sponsors can explain the likelihood or seriousness of a risk in plain terms where supported, describe what participants may feel or experience, and clarify when certain outcomes are unknown. This kind of transparent risk disclosure helps participants make informed choices and reduce IRB concerns about ambiguity or inconsistency.
Required elements: Compensation, alternatives, and key regulatory disclosures
Even well-written consent forms can be delayed if required elements are missing, incomplete, or difficult to locate. Sponsors should ensure that all required regulatory elements are included in a structured, easy-to-navigate format.
These elements typically include:
- Information about compensation and medical treatment in the event of research-related injury, when applicable.
- A clear statement that participation is voluntary, including the participant’s right to withdraw consent and discontinue participation at any time.
- A description of alternatives to participation.
- Confidentiality protections and how participant information will be handled.
- Contact information for study-related questions and participant rights.
- Any additional required disclosures relevant to the study.
The FDA’s draft guidance explicitly favors a clear, concise presentation that helps people understand why they may or may not want to join a study, which argues against burying critical disclosures in dense template language.
Compensation disclosure is especially important. The FDA’s draft guidance suggests that certain financial details may belong in key information when they could influence a prospective participant’s decision about whether to join the study, including:
- What participants will be paid.
- What expenses will be reimbursed.
- When payments will occur.
- Whether participants may be responsible for any study-related costs.
Vague or incomplete payment language, or a failure to distinguish clearly among compensation, reimbursement, and study-related costs, can lead to participant confusion and IRB stipulations.
For example, a participant should be able to understand whether:
- Payment is tied to completed visits.
- Travel reimbursement is a separate payment.
- Any procedures generate out-of-pocket costs.
- Compensation changes if they withdraw early.
This kind of clear compensation disclosure supports transparency, reduces misunderstanding, and makes it easier for IRBs to confirm that the presentation is fair and not misleading.
Ensuring protocol and informed consent consistency to avoid IRB delays
One of the most common reasons for delay in IRB approval is inconsistency between the protocol and the informed consent form, so sponsors should address discrepancies before submission.
These often appear in a few recurring areas, including:
- Study procedures.
- Visit schedules.
- Eligibility-related language.
- Risks, benefits, alternatives, or payment details.
These inconsistencies can be as simple as differences in how procedures, risks, or payment details are described across study documents.
Sponsors can reduce these inconsistencies by conducting a deliberate cross-document review before submission, which should include:
- The current protocol.
- Recruitment materials.
- Other participant-facing documents that align with the informed consent form.
This review should focus not only on major scientific content, but also on operational details.
A disciplined consistency review helps sponsors catch issues early, before they turn into formal stipulations. It also improves the overall quality of the submission package by showing that participant communication has been developed thoughtfully and in coordination with the study design.
Building consent materials that support faster, stronger review
A well-crafted informed consent form supports more than compliance. It helps participants understand the study, reinforces trust through transparency, and gives IRBs confidence that the sponsor has taken participant communication seriously. When the consent process is clear, risk disclosure is balanced, required elements are complete, and the document aligns with the protocol, sponsors are better positioned to reduce stipulations and move through IRB approval more efficiently.
As studies become more complex, the value of participant-centered informed consent only increases. Sponsors that invest early in clear, consistent, and IRB-ready consent materials can strengthen both ethical review and study startup performance.
This is part three of a six part series on A Sponsor’s Guide to IRB Approval. Explore more in this series by clicking any of the links below.
